All news

Evotec edges up premarket as analysts stay bullish

Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash

Evotec traded at EUR 2.98 premarket on Lang & Schwarz, up 0.34% from a EUR 2.97 close. The drug research company points to Just - Evotec Biologics as a key growth driver and expects milestone and licensing revenue from its pipeline. Analysts rate the stock 2 Buy, 1 Hold, 0 Sell, with a $4.52 target implying large upside for investors.

Read original source

EVO company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.